EGFR Molecular Classification In Vivo
- Conditions
- Molecular Imaging
- Registration Number
- NCT03031522
- Lead Sponsor
- Harbin Medical University
- Brief Summary
The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.
- Detailed Description
The goal of investigators were to evaluate the use of 18F-IRS as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-IRS in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- Advanced NSCLC
- 18 years or older
- A life expectancy of at least 12 weeks
- Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
- Written informed consent
- Claustrophobia
- Pregnancy
- Metal implants in the thorax
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method tumor SUVmax value of 18F-IRS PET/CT Imaging at time of imaging To quantify the accumulation, a volume of interest using a 3-D sphere, was placed over the primary lung tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal lung tissue as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University
🇨🇳Harbin, Heilongjiang, China
TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University🇨🇳Harbin, Heilongjiang, China